Human FGF21 ELISA Kit | EL-213-67621

Cat. No: EL-213-67621

$859.99 USD

96 wells

1
Target proteinFGF21
Gene ID26291
ReactivityHuman
Detection range7.82-500 pg/mL
Sample typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Sample volume100 µL
Assay time3h 20min
PrecisionIntra-assay CV <8%. Inter-assay CV <10%
ComponentsPre-Coated Microplate - 12 strips x 8 wells (4°C/-20°C)
Standard (Lyophilized) - 2 vials (4°C/-20°C)
Biotinylated Antibody (100×) - 120 μL (4°C/-20°C)
Streptavidin-HRP (100×) - 120 μL (4°C/-20°C)
Standard/Sample Diluent Buffer - 20 mL (4°C/-20°C)
Biotinylated Antibody Diluent - 12 mL (4°C/-20°C)
HRP Diluent - 12 mL (4°C/-20°C)
Wash Buffer (25×) - 20 mL (4°C/-20°C)
TMB Substrate Solution - 10 mL (4°C/-20°C (store in dark))
Stop Reagent - 6 mL (4°C/-20°C)
Plate Covers - 2 pieces (RT)
Storage4°C/-20°C

Download product sheet (PDF)

Safety Warning: Research Use Only. Not for diagnostic use.

This kit employs a sandwich enzyme immunoassay technique to quantify Human FGF21 in biological samples.

Introduction

FGF21 belongs to the fibroblast growth factor family but behaves atypically, circulating as a hormone rather than acting locally, and it does not require heparin for receptor engagement. Made primarily by the liver, it signals through a receptor complex built from an FGF receptor together with the co-receptor beta-Klotho, and this pairing drives glucose uptake into fat cells by boosting the GLUT1 transporter. Through this pathway FGF21 helps set whole-body glucose and lipid balance, and administering the recombinant protein in animal models lowers blood glucose, triglycerides, and cholesterol while improving sensitivity to insulin. Because of these effects, FGF21 is studied as a potential therapeutic strategy for metabolic disorders such as type 2 diabetes.

Principle of the Assay

This kit uses a sandwich enzyme immunoassay format in which the microtiter plate wells are pre-coated with a capture antibody specific to Human FGF21. Standards or samples are added to the appropriate wells along with a biotin-conjugated detection antibody that also recognizes Human FGF21. Avidin conjugated to horseradish peroxidase (HRP) is then added to each well and allowed to incubate. Upon addition of TMB substrate solution, a colorimetric signal develops only in wells where Human FGF21, the biotin-conjugated detection antibody, and avidin-HRP are all present. The enzymatic reaction is stopped by the addition of a sulphuric acid stop solution, and absorbance is measured spectrophotometrically at 450 nm (± 10 nm). Human FGF21 concentrations in the samples are then determined by comparing sample optical density values against a standard curve.